The FDA decision on Exelixis Inc.’s (EXEL) supplemental New Drug Application for Cabometyx tablets as a treatment for patients with previously treated advanced hepatocellular carcinoma is expected on January 14, 2019.Hepatocellular carcinoma (HCC), the most common type of liver cancer, is the fastest-rising cause of cancer-related death in U.S. It is the second-leading cause of cancer death worldwide, accounting for more than 700,000 deaths and nearly 800,000 new cases each year.Cabometyx, available in 3 strengths of 20mg, 40mg and 60mg, is already approved in the United States for the treatment of patients with advanced renal cell carcinoma. The drug is also approved in the European Union, Norway, Iceland, Australia, Switzerland, South Korea, Brazil and Taiwan for the treatment of advanced renal cell carcinoma (RCC) in adults who have received prior VEGF-targeted therapy, and in the European Union for previously untreated intermediate- or poor-risk advanced RCC.Cabometyx generated $324.0 million in net product revenue in full year 2017, and $428.3 million in the first nine months of 2018.EXEL closed Friday’s (Dec.21, 2018) trading at $17.72, down 3.70%.